Carsgen's first enrolled subject in the thank-u plus™ platform-based allogeneic car-t trial achieves scr at week 4

Shanghai , feb. 9, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first subject treated with an allogeneic bcma car-t therapy developed on the thank-u plus™ platform, has achieved stringent complete response (scr) and minimal residual disease (mrd) negativity at the day-28 assessment. the patient, diagnosed with relapsed/refractory multiple myeloma, iga-Λ type (r-iss stage ii), had previously undergone three lines of combination therapy along with autologous hematopoietic stem cell transplantation.
CAR Ratings Summary
CAR Quant Ranking